Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women

Nutrition

Volumn 24, Issue 2, 2008, Pages 120-126

  Rios, Danyelle R A ^a   Rodrigues, Edna T ^a   Cardoso, Ana P Z ^a   Montes, Marlise B A ^a   Franceschini, Sílvio A ^b   Toloi, Maria R T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

Coagulation; Fibrinolysis; Postmenopausal women; Soy isoflavone

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; CASEIN; D DIMER; DAIDZEIN; FIBRINOGEN; GENISTEIN; ISOFLAVONE DERIVATIVE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINE LEVEL;

AGED; ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD COAGULATION; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FACTOR VII; FACTOR X; FEMALE; FIBRINOGEN; FIBRINOLYSIS; GENISTEIN; HEMOSTASIS; HUMANS; ISOFLAVONES; MIDDLE AGED; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PHYTOESTROGENS; POSTMENOPAUSE; PROTEIN PRECURSORS; PROTHROMBIN;

EID: 37549059197     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2007.10.009     Document Type: Article

References (44)

1. National Institutes of Health. State-of-the-science conference statement: management of menopause-related symptoms. Ann Intern Med 142 (2005) 1003-1013
2. Colacurci N., Chiàntera A., Fornaro F., Novellis V., Manzella D., Arciello A., et al. Effects of soy isoflavones on endothelial function in healthy postmenopausal women. Menopause 12 (2005) 299-307
3. Hulley S., Grady D., Bush T., Furberg C., Herrington D.M., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-333
5. Boschetti C., Cortellaro M., Nencioni T., Bertolli V., Della Volpe A., and Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res 62 (1991) 1-8
6. Kroon U.B., Silfverstolpe G., and Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 71 (1994) 420-423
7. Caine Y.G., Bauer K.A., Barzegar S., ten Cate H., Sacks F.M., Walsh B.W., et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 68 (1992) 392-395
8. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., Virkamaki A., Hovatta O., Hamsten A., et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85 (2001) 619-5
9. de Valk-de Roo G.W., Stehouwer C.D.A., Meijer P., Mijatovic V., Kluft C., Kenemans P., et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women-a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19 (1999) 2993-3000
10. Koh K.K., Mincemoyer R., Bui M.N., Csako G., Pucino F., Guetta V., et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336 (1997) 683-690
11. Lien L.L., and Lien E.J. Hormone therapy and phytoestrogens. J Clin Pharm Ther 21 (1996) 101-111
12. Kass-Annese B. Alternative therapies for menopause. Clin Obstet Gynecol 43 (2000) 162-183
13. Glazier M., Gina M.B., and Bowman M.A. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 161 (2001) 1161-1172
14. Kulper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139 (1998) 4252-4263
15. Mackey R., and Eden J. Phytoestrogens and the menopause. Climacteric 1 (1998) 302-308
16. Murkies A.L., Wilcox G., and Davis S.R. Phytoestrogens. J Clin Endocrinol Metab 83 (1998) 297-303
17. Xu X., Wang H.J., Murphy P.A., and Hendrich S. Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. J Nutr 130 (2000) 798-801
18. Ososki A.L., and Kennelly E.J. Phytoestrogens: a review of the present state of research. Phytother Res 17 (2003) 845-869
19. Murphy P.A., Song T., Buseman G., Barua K., Beecher G.R., Trainer D., et al. Isoflavones in retail and institutional soy foods. J Agric Food Chem 47 (1999) 2697-2704
20. Cassidy A., Bingham S., and SetchelL K.D. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 60 (1994) 333-340
21. Nahas E.P., Neto J.N., De Luca L., Traiman P., Pontes A., and Dalben I. Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas 48 (2004) 372-380
22. Oliveira E.J., and Watson D.G. Chromatographic techniques for the determination of putative dietary anticancer compounds in biological fluids. J Chromatogr B Biomed Sci Appl 764 (2001) 3-25
23. Schall R. Estimation in generalized linear models with random effects. Biometrika 78 (1991) 719-727
24. Littell R.C., Milliken G.A., Sroup W.W., and Wolfinger R.D. SAS system for mixed models (1996), SAS Institute, Cary, NC
25. Lip G.Y.H. Fibrinogen and cardiovascular disorders. Q J Med 88 (1995) 155-165
26. Rock G., and Wells P. New concepts in coagulation. Crit Tev Clin Lab 34 (1997) 475-501
27. Noto D., Barbagallo C.M., Cefalu A.B., Cavera G., Sapienza M., Notarbartolo A., et al. Factor VII activity is an independent predictor of cardiovascular mortality in elderly women of a Sicilian population: results of an 11-year follow-up. Thromb Res 87 (2002) 206-210
28. Wilkes H.C., Meade T.W., Vickers M.R., Browne W., Walgrove M.A., Ruddock V., et al. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ 312 (1996) 473-478
29. Lindberg U.B., Crona N., Stigendal L., Teger-Nilsson A.C., and Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost 61 (1989) 65-69
30. de Valk-de Roo G.W., Stehouwer C.D.A., Emels J.J., Nicolaas-Merkus A., and Netelenbos C. Unopposed estrogen increases total plasma factor VII, but not active factor VII: a short-term placebo-controlled study in healthy postmenopausal women. Thromb Haemost 84 (2000) 968-972
31. Chandler W.L., Rodgers G.M., Sprouse J.T., and Thompson A.R. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med 126 (2002) 1405-1414
32. de Visser M.C.H., Poort S.R., Vos H.C., Rosendaal F.R., and Bertina R.M. Factor X levels, polymorphisms in the promotor region of factor X, and the risk of venous thrombosis. Thrmob Haemost 85 (2001) 1011-1017
33. Frishman W.H. Biologic markers as predictors of cardiovascular disease. Am J Med 104 (1998) 18S-27
34. Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40 (2005) 1215-1220
35. Norris L.A. Blood coagulation. Best Pract Res Clin Obstet Gynaecol 17 (2003) 369-383
36. Becker R.C. Understanding the dynamic of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. Am Heart J 149 (2005) S2-S8
37. Lip G.Y., and Lowe G.D. Fibrin D-dimer: a useful clinical marker of thrombogenesis?. Clin Sci 89 (1995) 205-214
38. Ridker P.M., Hennekens C.H., Cerskus A., and Stampfer M.J. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and risk of future myocardial infarction among apparently healthy men. Circulation 90 (1994) 2236-2240
39. Teede H.J., McGrath B.P., Smolich J.J., Malan E., Kotsopoulos D., Liang Y.L., et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 20 (2000) 1404-1409
40. Van Baal W.M., Emeis J.J., van der Mooren M.J., Kessel H., Kenemans P., and Stehouwer C.D.A. Impaired procoagulant-anticoagulant balance during hormone replacement therapy?. A randomized, placebo controlled 12 week study. Thromb Haemost 83 (2000) 29-34
41. Huber K., Christ G., Wojta J., and Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Thromb Res 103 (2001) S7-S19
42. Markiewicz L., Garey J., Adlercreutz H., and Gurpide E. In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem 45 (1993) 399-405
43. Teede H.J., Dalais F.S., Kotsopoulos D., McGrath B.P., Malan E., Gan T.E., et al. Dietary soy containing phytoestrogens does not activate the haemostatic system in postmenopausal women. J Clin Endocrinol Metab 90 (2005) 1936-1941
44. Dent S.B., Peterson C.T., Brace L.D., Swain J.H., Reddy M.B., Hanson K.B., et al. Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors. J Nutr 131 (2001) 2280-2287